Rising Prevalence of Zoonotic Diseases is Driving the Growth of the EMEA Solid Oral Veterinary Excipients Market

The rising prevalence of zoonotic diseases underscores the importance of maintaining the health of animals. Governments, veterinary organizations, and pet owners become more focused on preventing and treating diseases in animals to minimize the risk of transmission to humans. Zoonotic diseases, which can be transmitted between animals and humans, create a heightened awareness of the need for effective veterinary medications. Solid oral veterinary excipients play a crucial role in formulating medications that can be easily administered to animals to prevent or treat zoonotic diseases.

The prevention of zoonotic diseases often involves implementing preventive healthcare measures in animals. Solid oral dosage forms, such as tablets or capsules, allow for the convenient administration of medications, making it easier for pet owners and veterinarians to follow preventive healthcare protocols. The rising prevalence of zoonotic diseases is not limited to companion animals; it also affects livestock. The growing populations of both pets and livestock contribute to an increased demand for veterinary pharmaceuticals, including medications formulated with solid oral veterinary excipients.

Access Full Report @ https://www.databridgemarketresearch.com/reports/emea-solid-oral-veterinary-excipients-market

The EMEA Solid Oral Veterinary Excipients Market is expected to reach USD 300,011.11 thousand by 2031 from USD 187,632.69 thousand in 2023, growing with a CAGR of 6.2% in the forecast period of 2024 to 2031.

Key Findings of the Study

Technological Advancements in Excipient Formulations

Continuous technological advancements in the field of excipient formulations for veterinary medications present a myriad of opportunities for pharmaceutical companies. Innovations include the development of taste-masking agents, sustained-release formulations, and enhanced palatability enhancers. These advancements aim to address challenges related to the palatability and administration of solid oral veterinary medications. Taste-masking agents can make medications more palatable for animals, ensuring easier administration and improved compliance. Sustained-release formulations offer controlled and prolonged release of active ingredients, enhancing the efficacy and duration of therapeutic effects. Improved palatability enhancers contribute to a more positive medication experience for animals.

The advent of technological breakthroughs provides companies with the capability to create veterinary medications that go beyond conventional standards. These advancements not only enhance effectiveness and convenience but also address the evolving needs of veterinarians and pet owners. This results in an improved overall user experience, as companies are empowered to develop medications that align more closely with the requirements of modern veterinary care.

Report Scope and Market Segmentation

Segment Analysis:

The EMEA solid oral veterinary excipients market is segmented into functionality, origin type, formulation, animal, application, and distribution channel.

• On the basis of functionality, the market is segmented into binders, fillers and diluents, bulking agents, disintegrants, lubricants, coating agents, flavoring agents, colorants, buffering agents, and others

In 2024, the binders segment is expected to dominate the EMEA solid oral veterinary excipients market

In 2024, the binders segment is expected to dominate the market with 28.52% market share as the utilization of high-quality binders in various industries brings about enhanced cohesion, stability, and overall efficiency.

• On the basis of origin type, the market is segmented into organic chemicals and inorganic chemicals

In 2024, the organic chemical segment is expected to dominate the EMEA solid oral veterinary excipients market

In 2024, the organic chemicals segment is expected to dominate the market with a 63.85% market share due to the increasing demand for organic chemicals stems from their multifaceted benefits, including environmental sustainability, versatility in applications, and adherence to eco-friendly practices.

• On the basis of formulation, the market is segmented into tablets, capsule, and others. In 2024, the tablets segment is expected to dominate the market with 69.95% market share
• On the basis of animal, the market is segmented into farm animal and pet animal. In 2024, the farm animal segment is expected to dominate the market with 67.60% market share
• On the basis of application, the market is segmented into anti-infectives, anti-inflammatory drugs, nutritional supplements, and others. In 2024, the anti-infectives segment is expected to dominate the market with 50.69% market share
• On the basis of distribution channel, the market is segmented into direct tender, retail sales, and others. In 2024, the direct tender segment is expected to dominate the market with 72.66% market share

Major Players

Data Bridge Market Research analyzes JRS PHARMA (Germany), BASF Corporation (U.S.), Ashland (U.S.), Evonik Industries AG Germany), and Colorcon (U.S.) are the major players in the EMEA solid oral veterinary excipients market.

Market Development

• In December 2023, Merck KGaA introduced AIDDISON software, the inaugural AI solution designed to seamlessly integrate drug discovery and synthesis. This will accelerate the pace of drug development
• In June 2023, Ashland joined The University of Texas at Austin - College of Pharmacy and other pharmaceutical industry leaders of advanced extrusion technology at the Life Science Twin Screw Extrusion Workshop hosted by Leistritz Advanced Technologies Corp
• In February 2023, Kerry Group plc announced details of the consolidation of its distributor network across Europe. The company has chosen Azelis and Caldic as distribution partners for Kerry products to selected customers in the European region
• In May 2022, Croda International Plc, the company that uses smart science to create high-performance ingredients and solutions that improve lives, has today announced that its Health Care division will now become Croda Pharma. This brings Croda’s core specialty excipient portfolio together with the lipid delivery systems of Avanti Polar Lipids and the company’s adjuvant systems arm, all under one business
• In December 2022, the U.S. Food and Drug Administration accepted Soluplus branded excipient in its program to evaluate safety and acceptability of excipients for use in clinical trials, independent from a specific New Drug Application. This has helped the company to strengthen its product portfolio

Regional Analysis

Geographically, the countries covered in the EMEA solid oral veterinary excipients market report are Germany, France, Italy U.K., Spain, Russia, Netherlands, Belgium, Switzerland, Turkey, Rest of Europe, South Africa, Saudi Arabia, U.A.E., Algeria, Oman, Kuwait, and Rest of Middle East and Africa and Pakistan.

As per Data Bridge Market Research analysis:

Europe is the dominant and fastest-growing region in the EMEA solid oral veterinary excipients market

Europe is expected to dominate the market due to the presence of the largest consumer market with a high GDP. Moreover, it has the largest R&D spending globally and offers trade agreements with several countries, making it the largest market for consumer diagnosis and therapy products.

For more detailed information about the EMEA solid oral veterinary excipients market report, click here – https://www.databridgemarketresearch.com/reports/emea-solid-oral-veterinary-excipients-market